Affordable Access

Access to the full text

Epigenetic modulators from “The Big Blue”: A treasure to fight against cancer

Authors
Type
Published Article
Journal
Cancer Letters
Publisher
Elsevier
Publication Date
Sep 23, 2014
Volume
351
Issue
2
Pages
197–197
Identifiers
DOI: 10.1016/j.canlet.2014.06.005
Source
LBMCC
Keywords
License
Green

Abstract

Cancer remains a major public health problem in our society. The development of potent novel anti-cancer drugs selective for tumor cells is therefore still required. Deregulation of the epigenetic machinery including DNA methylation, histone modifications and non-coding RNAs is a hallmark of cancer, which provides potential new therapeutic targets. Natural products or their derivatives represent a major class of anti-cancer drugs in the arsenal available to the clinician. However, regarding epigenetically active anti-cancer agents for clinics, the oceans represent a largely untapped resource. This review focuses on marine natural compounds with epigenetic activities and their synthetic derivatives displaying anti-cancer properties including largazole, psammaplins, trichostatins and azumamides.

Report this publication

Statistics

Seen 109 times